Iovance Biotherapeutics, Inc.
IOVA
$3.30
$0.247.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 73.69M | 58.56M | 31.11M | 715.00K | 482.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.69M | 58.56M | 31.11M | 715.00K | 482.00K |
| Cost of Revenue | 45.54M | 39.82M | 31.37M | 7.26M | 4.37M |
| Gross Profit | 28.15M | 18.73M | -262.00K | -6.55M | -3.88M |
| SG&A Expenses | 42.50M | 39.55M | 39.57M | 31.39M | 29.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.27M | 147.62M | 133.02M | 118.44M | 121.74M |
| Operating Income | -86.58M | -89.07M | -101.91M | -117.72M | -121.26M |
| Income Before Tax | -77.00M | -85.06M | -98.56M | -114.38M | -118.14M |
| Income Tax Expenses | 1.56M | -1.52M | -1.46M | -1.41M | -1.76M |
| Earnings from Continuing Operations | -78.56M | -83.54M | -97.10M | -112.98M | -116.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.56M | -83.54M | -97.10M | -112.98M | -116.38M |
| EBIT | -86.58M | -89.07M | -101.91M | -117.72M | -121.26M |
| EBITDA | -78.06M | -80.50M | -93.44M | -110.11M | -114.40M |
| EPS Basic | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 |
| Normalized Basic EPS | -0.16 | -0.18 | -0.22 | -0.27 | -0.29 |
| EPS Diluted | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 |
| Normalized Diluted EPS | -0.16 | -0.18 | -0.22 | -0.27 | -0.29 |
| Average Basic Shares Outstanding | 304.89M | 303.27M | 284.82M | 266.22M | 255.95M |
| Average Diluted Shares Outstanding | 304.89M | 303.27M | 284.82M | 266.22M | 255.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
